Vanina de Verneuil sold $12k of VIR
EVP, General Counsel, Corp Sec at Vir Biotechnology, Inc.. 2,385 shares at an average of $5.16, traded Nov 5, 2025, filed Nov 7, 2025.
Score components
- +15RoleOfficer
- 0Trade size$12k at market
- 0Share of holdings soldSold 3.0% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-25-050592, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 5, 2025 | SOpen-market sale Common Stock10b5-1 | -2,385 | $5.16 | $12k | 78,210 | Nov 7, 2025 |
Related signals
Other insiders at Vir Biotechnology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Vir Biotechnology, Inc. | Marianne De Backer Chief Executive Officer | $141k 14,762 shares | -1% | |
| 9Weak | Vir Biotechnology, Inc. | Mark Eisner EVP and Chief Medical Officer | $34k 3,505 shares | -2% | |
| 24Weak | Vir Biotechnology, Inc. | Marianne De Backer Chief Executive Officer | $142k 19,039 shares | -2% | |
| 3Weak | Vir Biotechnology, Inc. | Mark Eisner EVP and Chief Medical Officer | $16k 2,089 shares | -1% | |
| 32Weak | Vir Biotechnology, Inc. | SVF Endurance (Cayman) Ltd owner | $1.1M 191,854 shares | -1% | |
| 21Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $132k 22,000 shares | -2% | |
| 32Weak | Vir Biotechnology, Inc. | SVF Endurance (Cayman) Ltd owner | $1.2M 189,431 shares | -1% | |
| 32Weak | Vir Biotechnology, Inc. | SVF Endurance (Cayman) Ltd owner | $2.9M 463,774 shares | -3% | |
| 23Weak | Vir Biotechnology, Inc. | Jason O'Byrne EVP & Chief Financial Officer | $38k 6,799 shares | -6% | |
| 20Weak | Vir Biotechnology, Inc. | Vicki L Sato director | $124k 22,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.